Johnson & Johnson Development Corporation (JJDC) is the corporate venture capital arm of Johnson & Johnson, one of the world's largest healthcare companies. JJDC invests strategically across pharmaceutical, medical device, and consumer health sectors with a focus on companies aligned with J&J's R&D and commercial priorities.

In neurotech, JJDC co-invested in Cala Health's $50M round in 2024 (non-invasive neuromodulation for tremor), alongside Vertex Growth, Nexus NeuroTech, and Action Potential Venture Capital. J&J's broader medtech portfolio includes neurovascular and neurosurgical devices through its DePuy Synthes and Cerenovus subsidiaries, making JJDC highly relevant for neurotech companies with clinical device applications.